The life sciences are in a period of dramatic change and innovation. Developments in new technologies, such as cell therapies and gene editing, are challenging traditional IP strategies and ...

The consultation on raising the threshold suggests that this change will “ensure that the BIT continues to target those ...

MERGE announces new Chair. MERGE, a Chicago-based integrated technology and marketing services provider, has a new board ...

Sanofi said in October last year that it was planning to spin off its consumer health business into a separate company before ...

Between digital therapeutics, HCP portals, and patient support communications, pharma companies are investing a significant ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former ...

Pharma regulators around the globe have different approaches to ensure companies meet drug safety laws and standards. Examining statistics on recent inspections gives insight into the common ...

Chris Rose of ProStrakan offers advice on selling in the pharmaceutical industry. The 80's and 90's spawned a host of selling models and most of us in the pharma business have been trained to use ...

EVERSANA has signed an agreement with Oracle Argus Cloud to add to the features of its pharmacovigilance platform, which ...

In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the ...